GLP 1 News and Research

RSS

Underutilized obesity treatments could transform patient health

When someone has obesity, losing even 5% of their body weight can make a major difference in their health -- especially if they can keep from regaining it.

21 Feb 2024

AMG 133 (maridebart cafraglutide) weight loss drug shows promise in early trial

AMG 133, an engineered bispecific molecule, demonstrated significant weight loss with a favorable safety profile in a phase 1 clinical trial, offering a promising new treatment option for obesity.

7 Feb 2024

New weight loss drug may be an effective strategy for preventing or treating high blood pressure

The new weight loss medication tirzepatide significantly lowered the systolic blood pressure (the top number in a blood pressure reading) for nearly 500 adults with obesity who took the medication for about eight months, according to new research published today in Hypertension, an American Heart Association journal.

5 Feb 2024

What does the future hold for obesity medication development?

The safety, clinical implications, and challenges of obesity pharmacotherapies based on entero-pancreatic hormone- treatments.

5 Feb 2024

Breakthrough obesity treatments on the horizon, rivaling surgery's success

New obesity pharmacotherapies, including GLP-1 receptor agonists and combinations of entero-pancreatic hormones, show promise in achieving significant weight loss, potentially rivaling bariatric surgery's effectiveness.

4 Feb 2024

Fermented foods linked to mental health benefits through gut-brain connection

Researchers explore the mental health benefits of fermented foods on the microbiota-gut-brain axis, highlighting the need for further studies to understand their therapeutic potential.

29 Jan 2024

Dietary factors influencing GLP-1 secretion: a new perspective in diabetes and obesity treatment

Researchers in The American Journal of Clinical Nutrition review the impact of diet on GLP-1 secretion in metabolic conditions like obesity and type 2 diabetes, highlighting its potential in treatment and prevention.

16 Jan 2024

Diabetes drugs may help curb alcohol dependence

In social media posts on the community network Reddit, users reported reduced cravings for alcohol when taking drugs intended to treat Type 2 diabetes and obesity.

8 Jan 2024

GLP-1R agonist liraglutide rapidly improves insulin sensitivity in pre-diabetics, independent of weight loss

A new study published in the journal Diabetes demonstrates that a glucagon-like peptide-1 receptor (GLP-1R) agonist, a member of a class of medication used to treat Type 2 diabetes and obesity, can lead to a rapid improvement in insulin sensitivity.

4 Jan 2024

MIT engineers develop 'vibing belly' pill to control appetite and curb obesity

When you eat a large meal, your stomach sends signals to your brain that create a feeling of fullness, which helps you realize it's time to stop eating.

26 Dec 2023

Diabetes drug may help women avoid weight gain after quitting smoking

The diabetes drug dulaglutide (Trulicity) may significantly lower a woman's risk of substantial weight gain after she has given up smoking, finds a secondary analysis of clinical trial data, published in the open access journal BMJ Nutrition Prevention & Health.

19 Dec 2023

From diabetes drug to anti-inflammation powerhouse: The unexpected evolution of GLP-1

Research pioneer Dr. Daniel Drucker has much to be proud of, as the GLP-1-based diabetes drugs hailing from his early research are named 2023 breakthrough of the year by the Science Magazine.

18 Dec 2023

Science’s Breakthrough of the Year: GLP-1 agonists can blunt obesity-associated health problems

Science has named the development of glucagon like peptide-1 (GLP-1) agonists and this year's discovery that these drugs can blunt obesity-associated health problems as its 2023 Breakthrough of The Year.

15 Dec 2023

How safe are GLP-1R agonists in early pregnancy?

JAMA Internal Medicine study examines the safety of GLP-1 receptor agonists and other second-line antidiabetic medications during early pregnancy, finding no significant increase in congenital anomalies compared to insulin use.

14 Dec 2023

Poll: Vast majority of older adults think health insurers should cover obesity medications

The vast majority of older adults – 83% -- think health insurers should cover medications that can help people with obesity manage their weight, a new poll of people age 50 to 80 finds.

13 Dec 2023

Tirzepatide shows success in maintaining weight loss in obese adults

Study finds that the anti-obesity medication tirzepatide effectively maintains weight loss in obese adults, offering a promising approach to managing obesity and related health complications.

12 Dec 2023

Adherence to second-line drugs for Type 2 diabetes can be hit or miss, study reports

Most patients with Type 2 diabetes will end up needing to add a second-line medication after metformin -; the go-to primary drug for glucose management -; to control their blood sugar levels.

12 Dec 2023

Tirzepatide maintains weight loss and improves cardiometabolic health in SURMOUNT-4 trial

The current class of anti-obesity drugs is proving remarkably effective at removing excess pounds. However, a phase 3 randomized clinical trial led by researchers at Weill Cornell Medicine and NewYork-Presbyterian found that people who stopped taking the medication regained much of that weight within a year.

11 Dec 2023

Second-line diabetes drugs safe for babies? New study offers reassurance

Infants born to women with pre-gestational type 2 diabetes who take second-line non-insulin antidiabetic medications (ADMs) during pregnancy are at no higher risk of major congenital malformations (MCMs) than infants born to those who take insulin, according to a new study led by Harvard T.H. Chan School of Public Health.